Last reviewed · How we verify
Angiotensin-Converting Enzyme Inhibitor
The Angiotensin-Converting Enzyme Inhibitor, marketed by Brigham and Women's Hospital, holds a significant position in the cardiovascular therapy market. A key strength is the protection of its core composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Angiotensin-Converting Enzyme Inhibitor |
|---|---|
| Also known as | ACE inhibitor, ACEi |
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN (PHASE2)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (PHASE3)
- Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
- The GUARDIAN Pilot Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: